Topical PRK 124 (0.125%) lotion for improving the signs and symptoms of rosacea.
BACKGROUND
Current treatments for acne rosacea are often associated with unsatisfactory outcomes and adverse effects.


OBJECTIVE
To determine the efficacy and tolerability of a new moisturizing lotion for improving the clinical signs and symptoms of mild-to-moderate acne rosacea.


METHODS
In a 12-week, open-label study, a moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK124 (0.125%, Pyratine-XR, Senetek PLC, Napa, CA) was applied twice daily to subjects with mild-to-moderate rosacea. Improvement in the appearances of erythema and papules were assessed by the treating physician. Skin barrier function was measured by transepidmal water loss after treatment. Tolerability and cosmetic outcome were evaluated by patients.


RESULTS
Twenty-one participants completed the study. Overall clinical improvement was observed in 80% of subjects, with most showing mild-to-moderate improvement. Erythema, papule counts, and telangiectasia were reduced. The reduction in TEWL was significant at weeks 4 (p = 0.01), 8 (p < 005), and 12 (p < 0.001). Rosacea symptoms (burning, stinging, dryness) were progressively reduced, with reduction in dryness achieving statistical significance at weeks 4 (p = 0.035), 8 (p = 0.037) and 12 (p = 0.016). Treatments were well tolerated and cosmetic outcomes were acceptable. Treatment-induced irritation was not observed.


CONCLUSIONS
The new moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK124 shows a continued trend toward improvement of skin barrier function and the appearances of erythema and papules associated with mild-to-moderate rosacea during 12 weeks of treatment.
Ortiz
Arisa
A
Department of Dermatology, University of California, Irvine, Irvine, CA 92697, USA. arisaortiz@gmail.com
Elkeeb
Laila
L
Truitt
Anne
A
Hindiyeh
Rasha
R
Aquino
Lisa
L
Tran
Minh
M
Weinstein
Gerald
G
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D003583:Cytokinins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012393:Rosacea / Q000188:drug therapy*
D003583:Cytokinins; D003879:Dermatologic Agents; C529130:pyratine 6